Company intelligence / Profile preview

NextGen Company

Moscow, Moscow, Russia

Ownership: Private
Development stage: Other

Overview

Nextgen is a Russian biotechnology company and a subsidiary of Artgen Biotech (formerly Human Stem Cells Institute). The company is best known for developing Neovasculgen, the world's first-in-class gene therapy drug for therapeutic angiogenesis, which is approved for the treatment of peripheral arterial disease and critical limb ischemia. Nextgen's platform focuses on plasmid-based gene therapies and gene-activated matrices for tissue regeneration, including bone defect restoration. The company is actively expanding its pipeline into new indications and international markets, including the EAEU, India, and the Middle East.

Therapeutic areas: CardiovascularRheumatologyOther
Modalities: Gene therapyDNA plasmid
Industry: Biotech

Partnerships

Artgen BiotechLomonosov Cluster

Beyond the preview

Go deeper on NextGen Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NextGen Company.

Explore the full profile